Podcast Episodes
Back to Search
Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook
For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of…
4 months, 1 week ago
Inside the sterile fill capacity crunch (Sponsored)
What does the future hold for sterile fill-finish CDMOs in a rapidly evolving market?
In this sponsored episode of The Top Line, Denis Johnson, CEO o…
4 months, 2 weeks ago
Trump's tariff threats, measured by manufacturing
Though uncertainty still surrounds the Trump administration’s pharmaceutical import tariffs, the trade rhetoric set off a clear response across the i…
4 months, 2 weeks ago
Why patient access must keep pace with drug innovation (Sponsored)
Biopharmaceutical innovation is advancing at an unprecedented pace, yet many patients still face barriers to accessing new medicines. In this episode…
4 months, 3 weeks ago
What were the biggest clinical trial flops of 2025?
Every clinical setback carries lessons. That’s why Fierce revisits major trial failures each year: not to dwell on disappointment, but to understand …
4 months, 3 weeks ago
Community oncology’s growing role in the future of cancer care (Sponsored)
Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patien…
5 months ago
The biggest potential drug launches of 2026
The leaders of this year’s list of the most anticipated drug launches will likely come as no surprise: Fierce’s annual report on the biggest potentia…
5 months ago
How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
Please see the following USPI, US ISI, EU SmPC and Canadian Product Monograph for complete LIVMARLI product information:
US Important Safety Informat…
5 months, 1 week ago
Why human expertise still matters in AI-driven med comms (Sponsored)
Artificial intelligence is reshaping medical communications, but it is not a substitute for human judgment. In this episode of The Top Line, experts …
5 months, 1 week ago
Biopharma's rebound keeping pace so far
In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry watchers…
5 months, 1 week ago